I am a medical oncologist and drug developer passionate about bringing practice-changing medicines to patients with cancer. As Vice President of Early Oncology Development at AstraZeneca, I am responsible for the strategic planning and execution of the early portfolio of oncology medicines.

I oversee a growing, global team including clinical projects, translational medicine and cancer biomarker development, and lead AstraZeneca’s diverse early-stage oncology portfolio, focused on solid tumour oncology.

I completed my medical training at Johns Hopkins University School of Medicine, Massachusetts General Hospital, and Memorial Sloan Kettering Cancer Center. In my previous role as an Attending Physician at Memorial Sloan Kettering Cancer Center, I focused on treating patients with lung cancer, developing novel immunotherapies, and identifying biomarkers for benefit to immunotherapy.

Those clinical and scientific successes were incredibly exciting and set me on the path to becoming a drug developer. I’m delighted to use that clinical grounding every day in the work we do at AstraZeneca.  

Our mission is to build the next generation of anti-cancer regimens to enable a future where we eliminate cancer as a cause of death. Our portfolio of medicines is purposefully diverse -- including antibody drug conjugates, radioconjugates, small molecules, immune-oncology agents, T cell engagers and cell therapies – in order to create orthogonal combination regimens which elicit deeper, more durable responses.

Matt Hellmann Vice President, Early Oncology Development, AstraZeneca
Headshot of Matt Hellmann, Vice President, Early Oncology Development, AstraZeneca

CURRENT ROLE

Vice President, Early Oncology Development, AstraZeneca

2023 – present

Serving as Vice President Early Oncology Development, Chair, Early Oncology Leadership Team and Co-Chair, Oncology Research Board AstraZeneca

2021 – present

Serving as Vice President, Early Oncology Clinical Group

2014 – 2021

Served as Attending Physician: Memorial Sloan Kettering Cancer Center, Thoracic Oncology Group and Early Drug Development Group

  Featured publications

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Memon D, Schoenfeld AJ , Ye D , Fromm G, Rizvi H, Zhang X, Keddar MR, Mathew D, Yoo KJ, Qiu J, Lihm J, Miriyala J, Sauter JL, Luo J, Chow A, Bhanot UK, McCarthy C, Vanderbilt CM, Liu C, Abu-Akeel M, Plodkowski AJ, McGranahan N, Łuksza M, Greenbaum BD, Merghoub T, Achour I, Barrett JC, Stewart R, Beltrao P, Schreiber TH, Minn AJ, Miller ML, Hellmann MD. Cancer Cell. 2024 Feb;42(2): 209–224.

Read More

Nivolumab plus ipilimumab in advanced non–small-cell lung cancer

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. N Engl J Med. 2019 Nov;381(21):2020-2031.

Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. J Clin Oncol. 2018 March;36(7):633-641.

Read More

Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer

Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin, LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD. Cancer Cell. 2018 May;33(5), 843–852.e4.

Read More

Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. N Engl J Med. 2018 May;378(22):2093-2104.

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. Science. 2015 April;348(6230):124-128.

Read More

Veeva ID: Z4-65546
Date of preparation: June 2024